ELABNYC 2014 Program Participants Adam Kirell & Erik Lillydahl: We are developing a portable biofeedback device designed to relieve and prevent symptoms of Temporomandibular Joint Disorder, Bruxism, and other stress related causes of facial pain. Alan Perlstein, Daisy Lobo, Mei-Mei Zhao & Xi Huang: [Polytechnic Institute of New York University affiliation] Ex Vivo Dynamics is a medical device company TM developing BloodGuard platform technology to significantly reduce short and long term complication resulting from blood transfusion. Amir Handzel: A decision support system for automated analysis and diagnosis of histopathology biopsies comprising a physical scanning platform, algorithms, and software. Ashish Raj: [Weill Cornell Medical College affiliation] BrainWire is a software based on brain MRI that can predict the future risk and patterns of Alzheimer’s and dementia, commercialized as an out-of-pocket elective procedure. Chang Kang: Disposable paper test sensors for fast detection of bacterial food spoilage. Daniel Leong: [Albert Einstein College of Medicine affiliation] Nutraceutical-based compound for the treatment of osteoarthritis. David Tsay: [Columbia University affiliation] Optical Coherence Tomography (OCT) guided interventional bioptome catheter and diagnostic system for the real-time diagnosis of cardiac diseases. Ekaterina Dadachova, Arturo Casadevall & Dina Tsukrov: [Albert Einstein College of Medicine affiliation] RadCure is developing effective, safe and affordable antibody-based drugs for curing HIV systemically and in the central nervous system. Gerard Honig, Bruce Hirsch & Andrew Sczesnak: The microbiome, a diverse community of symbiotic microbes which live in our bodies, protects us from infection. Symbiotic Health develops microbiome-based therapeutics for infectious diseases. Hsiou-Chi Liou, Samedy Ouk & Johannes Zakrzewski: [Weill Medical College of Cornell University & Memorial Sloan Kettering Cancer Center affiliation] Our mission at ImmuneTarget is to develop novel NF-kB/Rel inhibitor drugs for cancers and autoimmune diseases. Linh Le, Ly Vu & Nguyen Nguyen: [Stevens Institute of Technology affiliation] FlexTraPower designs and develops graphene-based sensors. The first application is a flexible sensor prototype for the thermometry market with sub-second response time and superior accuracy. Michael Tirgan & Nadereh Nouhi: [Rockefeller University Hospital affiliation] Focusing on developing new drugs for treatment of Keloid Disorder: 1) reformulating a generic drug into a sustained release product using nano-technology; 2) purifying plant extract to create a new topical cream. Rafael Gras, Tomas Aparicio Casado, Francesco Lotti & Jieling Zhu: [Columbia University Medical Center affiliation] Development of novel therapeutics using dendrimers – initial product will be topical gel for the prevention of HIV. Ravi Sachidanandam & Anitha Jayaprakash: [Icahn School of Medicine at Mount Sinai affiliation] Girihlet provides inexpensive, accurate mitochondrial (mtDNA) sequencing for personalized medicine. Service is based on our internal reference database on mtDNA heteroplasmy in various populations. Robert Ritlop & Adrian Trevisan: [NYU Stern affiliation] Oculogica is developing a portable, non-invasive, four-minute test to detect concussion, and other brain injuries, in the emergency room. Srdjan (Serge) Loncar: The mobile Health manager™ is a two-way SMS based patient engagement, medical therapy management, and care coordination platform, designed to improve outcomes patients on specialty pharmaceuticals. Steven Kaufman: Quikiks is the world’s first fully supportive footwear to enable people with various physical and cognitive challenges to don and doff their shoes totally hands-free. Tanjin Panna & David Putrino: [CUNY City College of New York affiliation] The mission of GesTherapy is to use low cost technologies to create affordable tele-rehabilitation systems to do physical therapy for millions of patients worldwide. W Vallen Graham: [Rockefeller University affiliation] I have harnessed a novel method to capture native protofibrillar amyloid structures to make a library of conformation-specific monoclonal antibodies that detect early amyloid disease. Zeynep Dereli-Korkut: [City College of New York affiliation] Our technology is a 3D microfluidic tumor array platform which will be used for highthroughput drug screening and patient specific treatment by evaluating the therapeutic response of biopsy samples.